Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
- 24 November 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (22) , 5767-5773
Abstract
Taliglucerase alfa (Protalix Biotherapeutics, Carmiel, Israel) is a novel plant cell–derived recombinant human β-glucocerebrosidase for Gaucher disease. A phase 3, double-blind, randomized, parallel-group, comparison-dose (30 vs 60 U/kg body weight/infusion) multinational clinical trial was undertaken. Institutional review board approvals were received. A 9-month, 20-infusion trial used inclusion/exclusion criteria in treatment-naive adult patients with splenomegaly and thrombocytopenia. Safety end points were drug-related adverse events: Ab formation and hypersensitivity reactions. Primary efficacy end point was reduction in splenic volume measured by magnetic resonance imaging. Secondary end points were: changes in hemoglobin, hepatic volume, and platelet counts. Exploratory parameters included biomarkers and bone imaging. Twenty-nine patients (11 centers) completed the protocol. There were no serious adverse events; drug-related adverse events were mild/moderate and transient. Two patients (6%) developed non-neutralizing IgG Abs; 2 other patients (6%) developed hypersensitivity reactions. Statistically significant spleen reduction was achieved at 9 months: 26.9% (95% confidence interval [CI]: −31.9, −21.8) in the 30-unit dose group and 38.0% (95% CI: −43.4, −32.8) in the 60-unit dose group (both P < .0001); and in all secondary efficacy end point measures, except platelet counts at the lower dose. These results support safety and efficacy of taliglucerase alfa for Gaucher disease. This study was registered at www.clinicaltrials.gov as NCT00376168.Keywords
This publication has 24 references indexed in Scilit:
- Recommendations for treating patients with Gaucher disease with emerging enzyme productsBlood Cells, Molecules, and Diseases, 2010
- Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseBlood Cells, Molecules, and Diseases, 2010
- Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?Genetics in Medicine, 2009
- A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imigluceraseAmerican Journal of Hematology, 2008
- The long-term international safety experience of imiglucerase therapy for Gaucher diseaseMolecular Genetics and Metabolism, 2007
- Therapeutic goals in the treatment of Gaucher diseaseSeminars in Hematology, 2004
- The Continuing Unethical Conduct of Underpowered Clinical TrialsJAMA, 2002
- Replacement therapy with imiglucerase for type 1 Gaucher's diseaseThe Lancet, 1995
- Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant SourcesAnnals of Internal Medicine, 1995
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991